Donor-Derived Tumor Associated Antigen-Specific T Cells in Treating Participants with Recurrent or Refractory Acute Lymphoblastic Leukemia

Inclusion Criteria

• Patients will be eligible to receive donor-derived multiTAA-specific T cells following any type of allogeneic HSCT as: * Adjuvant therapy for ALL (group A), or * Treatment for relapsed/residual ALL disease (group B)
• Residual disease at the time of transplant or post-transplant relapse is defined as polymerase chain reaction (PCR) positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry, or increased blasts on bone marrow biopsy or in the peripheral blood; minimal residual disease (MRD) will be defined as detection in blood or marrow of any of the following: * Any leukemia-specific marker (such as t(12;21); t(9;22) or t(4;11)) documented in the patient’s leukemia cells pre-transplant on a post-transplant evaluation * A leukemia-specific phenotype (e.g. expression of markers including CD10 and/or CD19 or CD3 and/or CD4 or CD8) post-transplant at a level of ≥ 0.01% * Mixed donor chimerism (> 20%)
• Life expectancy >= 6 weeks
• Karnofsky/Lansky score of >= 50
• Patient or parent/guardian capable of providing informed consent
• Bilirubin =< 2 x upper limit of normal
• Aspartate aminotransferase (AST) =< 3 X upper limit of normal
• Serum creatinine =< 2 x upper limit of normal
• Hemoglobin (Hgb) > 8.0 g/dL (can be transfused)
• Pulse oximetry of > 90% on room air
• Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ATL infusion; male partner should use a condom
• Available donor-derived multiTAA-specific T cell line
• No other investigational anti-neoplastic therapy for one month prior to entry in this study
• Undergoing stem cell transplant at Center for Cell and Gene Therapy (CAGT)
• DONOR ELIGIBILITY
• Donors for allogeneic (i.e. human leukocyte antigen [HLA] matched or mismatched related or unrelated) stem cell transplants who have fulfilled eligibility for and consented to stem cell donation as per the stem cell transplant program's standard operating procedures
• Subjects must be at least 12 kg or 24 pounds to be eligible for stem cell donation

Exclusion Criteria

• Patients receiving anti-thymocyte globulin (ATG) or Campath within 28 days of infusion
• Patients receiving a donor lymphocyte infusion within 4 weeks of planned T cell infusion
• Less than 30 days post-allogeneic stem cell transplant
• Severe intercurrent infection
• Evidence of graft versus host disease (GVHD) > grade II
• Pregnant or lactating
• Currently taking corticosteroids (> 0.5 mg/kg/day prednisone or equivalent)